论文部分内容阅读
通过调查、抽血检测男性20～65岁18000人,检出HBsAg+、AFP(-)、肝功能(ALT)基本正常的患者2065例,按地区随机分为补硒组1112例及对照组953例。补硒组每人每天服亚硒酸钠05mg1片,对照组则服安慰剂1片。通过服药前瞻观察2年,补硒组血硒显著升高,与对照组比较有明显差异(P<001);相应谷胱甘肽过氧化物酶随之升高,与对照组比较亦有显著差异(P<001);相反补硒组外周血淋巴细胞微核检出率显著低于对照组(P<001)。补硒组肝癌发病率170863/10万(19/1112),对照组430220/10万(41/953),有非常显著差异(P<001),进一步证实在肝癌高发区高危人群中,尤其是低硒地区,补硒可以预防肝癌,补硒方法简单,易于推广。
A total of 2065 patients with normal HBsAg+, AFP(-), and liver function (ALT) were detected through investigation and blood test. Among the 18,000 males aged 20 to 65 years, 1 216 selenium supplemented groups and 953 control subjects were randomly divided into regions. . Selenium supplemented sodium selenate (05 mg) per person per day in the selenium supplement group and placebo in the control group. After two years of prospective observation, selenium supplementation significantly increased selenium in blood, which was significantly different from that of the control group (P<001); accordingly, glutathione peroxidase was elevated and compared with the control group. The difference was statistically significant (P < 001). In the selenium supplement group, the detection rate of peripheral blood lymphocytes was significantly lower than that of the control group (P < 001). The incidence of hepatocellular carcinoma in the selenium supplement group was 170,863 per 100,000 (19/1112) and that in the control group was 430,220 per 100,000 (41/953), with a very significant difference (P<001), further confirming that among the high-risk population in the high-risk area of liver cancer, especially In areas with low selenium, supplementing selenium can prevent liver cancer, and the selenium supplementation method is simple and easy to promote.